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INTRODUCTION 
 
Oncogenic transformation is associated with 
alterations in cellular metabolism that are necessary to 
sustain rapid proliferation and survival in the hostile 
tumor microenvironment. These changes, also referred 
to as ‘metabolic transformation’, include increased 
rates of aerobic glycolysis, protein and lipid synthesis 
[1-3].  
A technique that has been especially useful in 
translating metabolic studies from cell models to 
humans is magnetic resonance spectroscopy (MRS), a 
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ABSTRACT: 
Molecular chaperone heat shock protein 90 (Hsp90) inhibitors are promising targeted 
cancer therapeutic drugs, with the advantage that they deplete multiple oncogenic 
client proteins and modulate all the classical hallmarks of cancer. They are now in 
clinical trial and show potential for activity in melanoma and other malignancies. Here 
we explore the metabolic response to Hsp90 inhibition in human melanoma cells 
using magnetic resonance spectroscopy. We show that, concomitant with growth 
inhibition and re-differentiation, Hsp90 inhibition in human melanoma cells is 
associated with increased glycerophosphocholine content. This was seen with both 
the clinical geldanamycin-based Hsp90 drug 17-AAG and the structurally dissimilar 
Hsp90 inhibitor CCT018159. The effect was noted in both BRAF mutant SKMEL28 and 
BRAF wildtype CHL-1 melanoma cells. Elevated content of the -CH2+CH3 fatty acyl 
chains and cytoplasmic mobile lipid droplets was also observed in 17-AAG-treated 
SKMEL28 cells. Importantly, the phospholipase A2 inhibitor bromoenol lactone 
prevented the rise in glycerophosphocholine seen with 17-AAG, suggesting a role for 
phospholipase A2 activation in the Hsp90 inhibitor-induced metabolic response. Our 
findings provide a basis for using metabolic changes as non-invasive indicators of 
Hsp90 inhibition and potentially as biomarkers of anticancer activity with Hsp90 
drugs in malignant melanoma and possibly in other cancers. 
 
Abbreviations used: 
BEL Bromoenol lactone; ERK Extracellular signal regulated kinase; GPC Glycerophosphocholine; GPE 
Glycerophosphoethanolmine; Hsp90 Heat shock protein 90; MAPK  Mitogen activated protein kinase; MRS Magnetic 
resonance spectroscopy; NTP Nucleotide triphosphate;  PC  Phosphocholine; PE Phosphoethanolamine; PLA2 
Phospholipase A2; PtdChoPhosphatidylcholine; SRB Sulforhodamine B  
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non-invasive methodology for studying a wide array of 
cellular metabolites. MRS studies have shown 
increases in levels of membrane phospholipid 
metabolism intermediates including phosphocholine 
(PC), phosphoethanolamine (PE),   
glycerophosphocholine (GPC) and 
glycerophosphoethanolamine (GPE) in cancer 
compared to normal tissues [4, 5]. These changes were 
recorded in cells, animal models and patients, 
suggesting their value as potential markers of 
malignant disease and response to therapy [4, 6].  
It is now widely accepted that these metabolic 
alterations occur as a result of the modulation of 
enzymes mediating phospholipid turnover, such as 
phospholipases A, C and D (catabolic pathway) and 
choline kinase and choline transport into cells (anabolic 
pathway) which have all been reported to be altered in 
malignancy as a result of oncoprotein activation [7, 8]. 
Furthermore, inhibition of oncogenic signaling by 
molecularly targeted anticancer agents produces 
changes in cellular phospholipid metabolism that are 
consistent with the induced molecular and cellular 
effects of the therapy (reviewed in ref [9]). Therefore, 
probing the metabolic effects of treatment with targeted 
agents should not only help to characterize the 
interactions between oncogenic signaling and tumor 
cell metabolism, but also provide a potential tool for 
monitoring the action of molecularly targeted drugs.  
Among the many targeted agents designed to block 
the activity of oncogenic proteins, inhibitors of the heat 
shock protein 90 (Hsp90) molecular chaperone are of 
special interest. These agents cause the simultaneous 
depletion of many oncogenic chaperone ‘client’ 
proteins, thus leading to the parallel blockade of 
several oncogenic pathways and multiple key cancer 
cell functions including proliferation, invasion and 
angiogenesis [10-12]. Several Hsp90 inhibitors have 
been identified, including the benzoquinone ansamycin 
derivative 17-allylamino-17-demethoxygeldanamycin 
(17-AAG, tanespimicin), as well as the prototype of the 
pyrazole/isoxazole resorcinol class CCT018159 which 
is a precursor of the resorcinylic isoxazole amide 
clinical candidate NVP-AUY922 [13-16].  
17-AAG has shown promising antitumor activity in 
numerous preclinical models, and is currently 
undergoing clinical testing with evidence of activity in 
trastuzumab-refractory breast cancer [17-19]. In 
addition, preclinical studies indicated that 17-AAG has 
therapeutic activity against melanoma cells, most likely 
via effects on the RAF family of oncoproteins [20, 21]. 
Early clinical studies revealed evidence of Hsp90 target 
modulation and some signs of biological activity 
(stable disease) in melanoma patients that may 
potentially be associated  with the presence of BRAF 
or NRAS mutation [17, 22]. Interestingly, mutant 
BRAF, which is present i n  a l m o s t  7 0 %  o f  a l l  
melanomas,  shows marked dependency on Hsp90 and 
is degraded by 17-AAG treatment, while WT BRAF 
activated by NRAS is also Hsp90 dependent [20]. 
Furthermore, melanoma cells, regardless of their 
BRAF or NRAS mutation status, are sensitive to the 
growth inhibitory effects of 17-AAG (21), consistent 
with the action of Hsp90 inhibitors on multiple 
oncoproteins, including CRAF. A recent phase II 
clinical study reported a lack of activity of 17-AAG in 
melanoma which may be attributed to the treatment 
dose and schedule not achieving sustained depletion of 
BRAF/CRAF kinases [23]. The authors recommended 
that future trials in melanoma should focus on more 
potent Hsp90 inhibitors or a 17-AAG formulation that 
can be administered chronically for a more prolonged 
suppression of the extracellular signal-regulated 
kinase1/2 (ERK1/2) mitogen activated protein kinase 
(MAPK) pathway.  
In this study, we wished to study in more depth the 
effects of Hsp90 inhibitors in human melanoma cells, 
and in particular to explore the effects of Hsp90 
inhibition on cell metabolism, which may potentially 
provide a means for further characterizing the 
anticancer activity of these agents in the clinical 
setting.  
Membrane phospholipid metabolism is tightly 
linked to cell proliferation and survival [24, 25] and is 
altered with malignancy and following anticancer 
treatment [9, 26]. In melanoma, choline-containing 
derivatives of phospholipid metabolism show distinct 
profiles during growth inhibition by chemotherapy 
versus subsequent adaption to treatment [27]. This 
suggests that phospholipid metabolism may be a 
mediator of cell response/adaptation to treatment [27].  
Using MRS, we have previously shown that 
inhibition of Hsp90 with 17-AAG in human colon 
carcinoma cells correlated with alterations in 
phospholipid metabolism; an elevation in PC and GPC 
levels in vitro, and PC+PE levels in vivo [28]. In other 
studies, however, 17-AAG treatment caused a decline 
in total choline levels (comprised of choline, PC and 
GPC) in prostate cancer xenografts [29] and the rates 
of radiolabelled-choline uptake and phosphorylation in 
human colon cancer cells which would be expected to 
produce a decrease in cellular PC [30]. The basis for 
these apparent discrepancies is unclear but could relate  
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to variations in the genetic profiles and drivers of the 
various cancer cell lines studied or to differing 
downstream cellular effects of the therapy, such as 
differentiation or inhibition of growth versus induction 
of apoptosis [13. 31].  
Here we explore the metabolic consequences of 
Hsp90 inhibition in human melanoma cells. Our aims 
were to characterize any metabolic changes in relation 
to the cellular and molecular effects induced post-
Hsp90 inhibition, and to explore the mechanistic basis 
that could give rise to them.  Our findings show that 
inhibition of Hsp90 in human melanoma cells with 17-
AAG and CCT018159 is associated with reduced 
proliferation and induction of cell differentiation. 
These effects correlated with an elevation in cellular 
GPC and cytoplasmic lipid droplets which may be 
associated with activation of calcium-independent 
phospholipase A2 (iPLA2). 
 
MATERIALS & METHODS 
 
Cell Culture 
 
  Human malignant melanoma SKMEL28 cells 
(with V600E  mutant BRAF, WT NRAS) were 
obtained from ATCC, and CHL-1 cells (with WT 
BRAF, WT NRAS) were a gift from Prof Richard 
Marais (Institute of Cancer Research, London). Both 
cell lines were cultivated in DMEM containing 10% 
(v/v) heat inactivated fetal calf serum, 100 U/ml 
penicillin and 100 g/ml streptomycin (Life 
Technologies; Paisley, UK) and monthly screened for 
mycoplasma.  
 
Analysis of cell growth inhibition, cell volume and 
cell cycle profiles 
 
Cell counts and diameter measurements were 
performed on a Beckman Coulter Vi-Cell Cell 
Viability Analyzer. The impact of the Hsp90 inhibitors 
17-AAG (Alexis; Exeter, UK) and CCT018159 
(Calbiochem; Nottingham, UK) on cell proliferation 
was assessed using the sulforhodamine B (SRB) assay 
following a 144h exposure to a range of drug 
concentrations as previously described [32]. The effect 
of Hsp90 inhibition on cell cycle profiles was assessed 
by flow cytometry using propidium iodide staining and 
standard procedures as previously described [32]. 
 
Western Blotting 
The level of client protein expression following Hsp90 
inhibition was assessed by Western blotting as 
previously described [32]. The primary antibodies used 
were anti-Hsp70 (Stressgen Bioreargents; Michigan, 
USA), anti-CRAF, anti-BRAF, anti-CDK4 (Santa Cruz 
Biotechnology; Santa Cruz, CA, USA), anti- total and 
phosphorylated cytosolic phospholipase A2 (cPLA2, 
Cell Signalling Technology; Danvers, MA, USA), anti-
tyrosinase and anti-gp100 (Abcam; Cambridge, UK) 
and anti-GAPDH (Chemicon; Hampshire, UK) 
antibodies. The secondary antibodies used were anti-
mouse for BRAF, Hsp70 and GAPDH and anti-rabbit 
for CRAF, CDK4, cPLA2, phospho-cPLA2, tyrosinase 
and gp100 (GE Healthcare Life Sciences; 
Buckinghamshire, UK).  
 
Analysis of Cell Morphology 
 
Bright field images of control and treated cells were 
acquired on a Zeiss Axiovert inverted light microscope 
(Carl Zeiss Ltd.; Hertfordshire, UK) connected to a 
Cool SNAP Pro Color digital camera (Media 
Cybernetics; Bethesda, MD, USA), and cells visualized 
using Image Pro Plus software (Media Cybernetics) 
version 6.2.0424. 
 
Cell treatment and extraction for MRS analyses 
 
Logarithmically growing SKMEL28 and CHL-1 
cells were treated with 100 nM or 39 nM 17-AAG 
respectively for 48h to achieve modulation of Hsp90 
client proteins and a ca. 50% reduction in cell counts. 
SKMEL28 cells were further treated with 15 μM 
CCT018159 for 48h. Control cells were exposed to 
DMSO at a concentration of 0.1%. In subsequent 
experiments, 17-AAG treated cells were co-incubated 
with 20 μM of the calcium-independent phospholipase 
A2 (iPLA2) specific inhibitor bromoenol lactone (BEL, 
Sigma-Aldrich) for the last 24h of treatment. 
 
At the end of each experiment cells were washed in 
cold saline and extracted in equal volumes of cold 
methanol, chloroform and water. Lyophilised samples 
of the water-soluble phase were reconstituted in 540 l 
of a D2O solution containing 0.075% (w/v) 3-
(trimethylsilyl)propionic-2,2,3,3-d4 acid as internal 
reference for analysis by 
1H MRS. Following 
acquisition of 
1H spectra, the sample volume was 
topped up to 600 l with a D2O solution containing 
EDTA and methylenediphosphonic acid (internal 
standard) to a final concentration of 10 mM and 0.43  
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mM respectively at pH 8.2 for analysis by 
31P MRS. 
The lipid fraction of cell extracts was reconstituted in 
CDCl3 containing 0.56 mM trimethyl silane as an 
internal standard. 
 
MR Spectroscopy Measurements 
 
1H MR spectra were acquired at room temperature 
on a 500 MHz Bruker spectrometer using a 30º flip 
angle, a 1s repetition delay (RD), a spectral width of 13 
ppm and 64 K data points under conditions of water 
signal suppression for aqueous samples. 
31P MR 
spectra were acquired using power gated composite 
pulse 
1H decoupling, a 30º flip angle, a 1s RD, a 
spectral width of 100 ppm and 32 K data points. 
Spectra were processed using MestRe-C version 2.3. 
(University of Santiago de Compostela, Spain), 
applying a 1Hz line broadening for 
31P spectra. 
Metabolite content was determined by peak integration, 
normalized relative to the internal standard and 
corrected for cell number and volume and for 
saturation in the case of the 
31P MR spectra. 
 
Mobile lipid staining and confocal microscopy 
 
For the detection of neutral mobile lipids, 
SKMEL28 cells were grown on glass coverslips in 
four-well plates and treated with vehicle or 17-AAG as 
indicated above. At the end of the incubation, cells 
were washed in PBS then fixed in 4% 
paraformaldehyde followed by incubation in a 1μg/ml 
solution of Nile red (Sigma-Aldrich) for 15min. Cells 
were then washed three times in a PBS solution 
containing the nuclear stain Topro-3 (Molecular 
Probes; Paisley, UK), then mounted on a slide. 
Fluorescent images were acquired on a Leica SP1 
confocal laser scanning microscope using 488 nm and 
633 nm excitation, and 530 nm and 670-720 nm 
emission wavelengths for Nile red and Topro-3 
respectively. Cells were visualized using the Leica 
Confocal software version 2.61. Quantitation of the 
number of lipid droplets per cell was performed using 
ImageJ (National Institutes of Health, USA) version 
1.42q and analysis of a minimum of 15 cells per image. 
 
Statistical Analysis 
 
The statistical significance of the results was 
assessed using an unpaired 2-tailed Student t-test with 
p values ≤ 0.05 considered to be significant. Data are 
represented as the mean  standard deviation.  
 
RESULTS 
 
Hsp90 inhibition induces growth arrest and 
differentiation concomitant with depletion of 
oncogenic client proteins  
 
SRB assay of growth inhibition following treatment 
with 17-AAG indicated that the drug reduced cell 
proliferation in the two human melanoma cell lines 
studied, with GI50 values of 21±5 nM for the BRAF 
mutant SKMEL28 cells and 13±2 nM for the BRAF 
WT CHL-1 cells. Thus 17-AAG has broadly similar 
potency in the two melanoma cell lines. This is in 
agreement with findings from previous studies in larger 
melanoma cell line panels showing no dependence of 
sensitivity to 17-AAG on BRAF mutation status [20, 
21].  
Western blotting demonstrated the expected 
molecular signature of Hsp90 inhibition in both 
melanoma cell lines as shown by depletion of the client 
proteins CRAF, BRAF and CDK4 and induction of 
Hsp70 following exposure to 17-AAG, thus confirming 
inhibition of Hsp90 under the conditions used in our 
experiments (Figure 1A, top panel). To confirm that 
the effects were not restricted to one chemotype, the 
resorcinylic pyrazole Hsp90 inhibitor CCT018159 [16, 
33] also inhibited growth in SKMEL28 cells with a 
GI50 value of 3.4±1.3 μM and induced similar 
molecular effects as 17-AAG in this melanoma line 
(Figure 1A). 
Of interest, inhibition of Hsp90 resulted in 
induction of differentiation in the melanoma lines used, 
as shown by the characteristic increase in the dendritic 
cell morphology and expression of the melanocyte 
lineage marker tyrosinase in both CHL-1 and 
SKMEL28 cells (Figure 1A, lower panel and B). The 
levels of gp100, another melanoma differentiation 
marker, were undetectable in CHL-1 cells but 
significantly induced post-17-AAG treatment in 
SKMEL28 cells. Basal phospho-ERK1/2 levels were 
much lower in CHL-1 compared to SKMEL28 cells 
but decreased substantially post-exposure to 17-AAG 
in both cell lines and to CCT018159 in SKMEL28 cells 
(Figure 1A lower panel) consistent with reduced 
ERK1/2 MAPK signaling post Hsp90 inhibition.  
As shown in Figure 1C, flow cytometry analysis of 
cell cycle profiles indicated that at the concentrations 
and treatment durations used, 17-AAG caused an 
increase in the G1 cell phase of the cell cycle and a 
corresponding reduction in the S phase population in  
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SKMEL28 cells (n=3, p0.002). There was a small 
increase in the G1 cell population and a reduction in 
the S phase fraction in CHL-1 cells exposed to 17-
AAG but these effects were not statistically significant 
(n=5, p0.27).  
 
Hsp90 inhibition leads to altered cellular choline 
phospholipid metabolism 
 
Next, to evaluate cellular choline phospholipid 
metabolism following Hsp90 inhibition, we analyzed 
the 
1H and 
31P MR spectra of the aqueous metabolites 
from control and Hsp90 inhibitor-treated melanoma 
cells. 
1H MRS analysis indicated that the most prominent 
and consistent effect observed following 17-AAG 
treatment was a rise in GPC levels of up to 2.5-fold in 
SKMEL28 and CHL-1 cells (Figure 2A and B). PC 
levels remained unchanged in both cell lines (p0.35). 
Consequently, the PC/GPC ratio decreased by half in 
both SKMEL28 and CHL-1 cells (Figure 2C). Similar 
effects were also recorded by 
31P MRS as summarized 
in Table 1.  
1H MRS analyses also indicated that SKMEL28  
Fig. 1: The effect of Hsp90 inhibitors on protein expression, cell morphology and cell cycle
profiles in human melanoma cell lines. 
A) Western blot analysis showing the expression of Hsp90 client proteins, Hsp70 (top panel), phospho-ERK1/2,
tyrosinase and gp100 in cells treated with 17-AAG (SKMEL28 and CHL-1), and CCT018159 (SKMEL28) for 48h
at the concentrations indicated in the text.  
B) Bright field microscopy images showing the increased dendritic morphology (black arrows point to dendrites)
of SKMEL28 cells following exposure to 100nM 17-AAG treatment for 48h. C) DNA histograms and a table
showing cell cycle distributions in SKMEL28 and CHL-1 cells following exposure to vehicle or 17-AAG (100nM
and 39nM respectively) for 48h. * p0.002.  
  
www.impactjournals.com/oncotarget    190      Oncotarget 2010; 1: 185-197 
 
text  
Fig.2: The effect of the Hsp90 inhibitor 17-AAG on 
1H MRS detectable cellular choline
metabolites in human melanoma cell lines. 
A) 1H MR spectra from the aqueous phase of cell extracts showing the choline region in control and 17-AAG
treated SKMEL28 (left) and CHL-1 (right) cells.  
B) A histogram showing increased GPC content following 17-AAG treatment in SKMEL28 and CHL-1 cells while
PC levels remain unchanged.  
C) A histogram showing decreased PC/GPC in 17-AAG treated SKMEL28 and CHL-1 cells relative to their
vehicle-treated controls. **p<0.01. 
Table 1: The effect of the Hsp90 inhibitor 17-AAG on the 31P-containing water soluble 
metabolites in SKMEL28 and CHL-1 human melanoma cells. 
Metabolites 
(mM) 
SKMEL28 (n=4)  CHL-1 (n=5) 
Control  17-AAG  p  Control  17-AAG  p 
PC  19.9±1.3  17.1±8.1  0.69  11.3±3.5  9.5±2.9  0.38 
GPC  2.9±1.6  7.4±2.8*  0.013  6.7±1.8  9.6±1.6*  0.015 
GPE  1.2±1.1  2.4±0.3  0.18  1.5±0.3  1.3±0.4  0.63 
NTP  9.4±0.8  6.7±1.2*  0.006  8.6±2.4  8.1±2.8  0.82 
NOTE: Metabolite levels represent average concentration in control or treated cells expressed as the mean μ SD.  
* Statistically significant difference (p<0.05, t-test) between control and treated cells.  
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cells exhibited similar metabolic profiles to those 
seen with 17-AAG when exposed to the alternative 
chemotype Hsp90 inhibitor CCT018159, with the GPC 
content increasing to 240±65% relative to the controls 
(n=5, p=0.008). There was a trend towards an increase 
in PC content (152±46%) although this did not reach 
statistical significance (p=0.067). The PC/GPC ratio 
was reduced to 67±23% relative to vehicle treated 
controls (p=0.03).  
 
Hsp90 inhibition correlates with increased fatty 
acid signals and cytoplasmic lipid droplets 
 
GPC is formed following the breakdown of the 
membrane phospholipid phosphatidylcholine (PtdCho) 
via PLA2 and subsequently via lysophospholipase, 
leading to simultaneous release of free fatty acids (25). 
To investigate the basis for the rise in GPC, we 
analyzed the lipid metabolites of 17-AAG-treated 
SKMEL28 cells by 
1H MRS. This revealed no 
differences in the levels of PtdCho (104±13%; n=7, 
p=0.4) but the levels of the -CH2 free fatty acyl chains 
increased reproducibly by 1.35-fold relative to the 
control (p=0.02). The content of the –CH3 chains and 
the poly-unsaturated fatty acid signals at 5.3 ppm was 
also increased by 1.65-and 1.3-fold respectively, 
although this did not reach statistical significance (n=7, 
p=0.07 and p=0.14 respectively). The ratio of –
(CH3+CH2)/PtdCho increased by 1.35-fold relative to 
the control (p=0.0055) (Figure 3A and B).  
To further characterize the changes in lipids 
observed by MRS, we performed Nile red staining on 
SKMEL28 cells following exposure to the 17-AAG. 
Analysis by confocal microscopy revealed an increase 
in the staining originating from cytoplasmic mobile 
lipid droplets following treatment with 17-AAG 
compared to vehicle treated control cells (Figure 4A). 
Quantitation showed an increase in the number of lipid 
droplets by ~6.5-fold compared to the control (n=3, 
p=0.033). This result corroborates the 
1H MRS-
observed increase in fatty acyl chain signals post 17-
AAG treatment and indicates that these are likely to be 
present within cytoplasmic mobile lipid stores.   
 
The metabolic effects of Hsp90 inhibition may be 
associated with calcium-independent PLA2 
activation 
 
The increase in GPC coupled with the rise in 
mobile lipids induced by 17-AAG pointed to activation 
of PLA2 following Hsp90 inhibition. To confirm this, 
we assessed the effect of 17-AAG on the level of 
expression and activation (by phosphorylation) of 
cytosolic calcium-dependent PLA2 (cPLA2), a widely 
studied and well characterized member of the PLA2 
family (34). Interestingly, Western blotting showed a 
reduction in the expression of cPLA2 together with a 
marked decline in the levels of phospho-cPLA2 in 
SKMEL28 cells following exposure to 17-AAG, 
indicating reduced activity of the enzyme (Figure 5A). 
Therefore, it is unlikely that the metabolic changes 
observed following treatment with 17-AAG could be 
related to cPLA2 activation. 
We next tested the involvement of cytosolic  
Fig.3: 
1H analysis of lipid metabolites in SKMEL28 human melanoma cells exposed to 17-AAG. 
A) Representative 1H MR spectra from the lipid fraction of control and 17-AAG-treated SKMEL28 cell extracts
displaying the 0.5-3.8ppm region. 
B) A summary showing increased fatty acid signal intensities following exposure to 17-AAG. * p<0.05, ** p<0.01,
# p=0.07.  
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a  
Fig. 4: Changes in cytoplasmic lipid droplets in SKMEL28 human melanoma cells following 17-
AAG treatment.  
A) Confocal microscopy images of control and 17-AAG-treated SKMEL28 cells stained with Nile red (procedure
described in Materials and Methods) showing staining intensity from cytoplasmic lipid droplets (white arrows).  
B) Quantitative analysis of the number of cytoplasmic lipid droplets in control and 17-AAG-treated cells.
*p=0.033. 
Fig. 5: The involvement of PLA2 activity in mediating the metabolic effects of 17-AAG. 
A) Western blots showing a decrease expression of cPLA2 and phospho-cPLA2 in SKMEL28 following
exposure to 17-AAG. A histogram showing that the specific iPLA2 inhibitor BEL is able to prevent the rise in
GPC after 17-AAG treatment, with no significant effect on the other metabolites (as detected by 31P MRS
analysis). * p=0.01, #p=0.076, NS p0.37.  
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calcium-independent PLA2 (iPLA2), another key 
regulator of membrane lipid metabolism [34], and 
assessed whether the effect on GPC could be reversed 
by co-treatment with the iPLA2 specific inhibitor BEL 
[34].  
Western blotting showed that the levels of Hsp90 
client protein depletion and differentiation marker 
induction were comparable in melanoma cells treated 
with 17-AAG+BEL versus 17-AAG alone (data not 
shown).  In addition, cell counts per flask relative to 
the control were also similar (40±6% for 17-AAG and 
34±14% for 17-AAG+BEL, p=0.46). MRS analysis 
indicated that, as shown in Figure 5B, co-incubation of 
SKMEL28 melanoma cells with 17AAG+BEL 
prevented the rise in GPC seen with 17-AAG alone 
(n=4, p=0.01). PC levels showed a slight increase in 
17-AAG+BEL treated melanoma cells compared to 
cells treated with 17-AAG alone although this effect 
was not statistically significant (p=0.076). No 
significant alterations were noted in the levels of GPE 
or NTP in cells treated with 17-AAG+BEL versus 17-
AAG on its own (p0.37, Figure 5B). 
These observations suggest that the rise in GPC 
recorded with 17-AAG may be related to iPLA2 
activation following Hsp90 inhibition. 
 
DISCUSSION 
 
Studies using MRS have shown characteristic 
changes in choline phospholipid metabolism in tumor 
versus normal tissues, which extend from cell and 
animal models to humans. In particular, increases in 
levels of PC and the PC/GPC ratio have been reported 
to occur with increased malignant potential [7, 26]. 
This ‘metabolic signature’ has been linked to changes 
in enzyme activities governing the rate of choline 
transport and phosphorylation (e.g. choline kinase) as 
well as membrane phospholipid breakdown (PLA, C 
and D) which occur following oncogene activation and 
the acquisition of a malignant phenotype [7, 8, 35]. In a 
melanoma model, alterations in the phospholipid 
metabolic phenotype were observed during initial 
response to chemotherapy versus subsequent 
adaptation of tumors to treatment. Specifically during 
the growth inhibition phase, a rise in levels of PC+PE 
and GPC+GPE was recorded while the re-growth phase 
was characterized by an increase in PC+PE only. It is 
therefore plausible that changes in tumor phospholipid 
profiles could be implicated in tumor survival and 
adaptation to therapy [27].  
In this study we evaluate the metabolic 
consequences that follow inhibition of Hsp90, a 
molecular chaperone involved in maintaining the 
stability, conformation and activatable state of several 
oncogenic proteins involved in the initiation and 
maintenance of the malignant phenotype [10-12].  We 
used the clinical Hsp90 inhibitor 17-AAG and the 
prototype resorcinylic pyrazole CCT018159 Hsp90 
inhibitor in human melanoma cells to study the effects 
of inhibition of the molecular chaperone on 
phospholipid metabolism, and to explore the cellular 
and biochemical processes that give rise to them.  
Two human melanoma cell lines were used: CHL-1 
with WT BRAF/WT NRAS and SKMEL28 with 
V600E mutant BRAF/WT NRAS. We selected these 
lines because mutant BRAF is highly sensitive to 
Hsp90 inhibition although melanoma cells regardless 
of their BRAF status are also growth inhibited by 
agents such as 17-AAG, most likely because of 
depletion of CRAF as well as BRAF, in addition to 
effects on other client proteins [20, 21].  
Growth inhibition assays on SKMEL28 and CHL-1 
cells showed no major differences in the potency of 17-
AAG between the two cell lines, consistent with 
previous studies in larger panels showing that mutant 
BRAF is not a predictive marker for sensitivity to 
Hsp90 inhibitors in human melanoma cell lines [20, 
21].   
Further assays were conducted to determine the 
time and drug concentration required to achieve the 
characteristic molecular signature of Hsp90 inhibition 
(reduction in CRAF, BRAF and CDK4 as 
representative client proteins together with induction of 
Hsp70) as well as to cause a decrease in cell counts to 
~50% of controls. Interestingly, inhibition of Hsp90 
with both 17-AAG and CCT018159 was associated 
with induction of cell differentiation as indicated by the 
increased expression of the melanocyte lineage 
markers tyrosinase and gp100 (involved in melanin 
synthesis and deposition) and the increase in the 
dendritic cell morphology [36]. These observations are 
in agreement with the previously reported effects of 
Hsp90 inhibition on cell differentiation status in human 
breast cancer cells [31]. 
We next examined the metabolic features 
characteristic of cells exhibiting the molecular and 
cellular effects of Hsp90 blockade.
 1 H and
 31P MR 
analyses of extracts from SKMEL28 and CHL-1 cells 
indicated that 17-AAG treatment resulted in an 
increase in cellular levels of GPC in the two cell lines 
while PC levels remained unchanged. The PC/GPC  
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ratio was also reduced in both cell lines. Similar 
changes in GPC and PC/GPC were also obtained with 
the more recently developed and structurally dissimilar 
Hsp90 inhibitor CCT018159 in SKMEL28 melanoma 
cells. Demonstration of the same effects with two 
different Hsp90 inhibitor chemotypes provides further 
support for a mechanism involving pharmacologic 
modulation of the molecular chaperone. This metabolic 
signature correlated with inhibition of Hsp90 and 
downstream growth arrest and induction of 
differentiation in both melanoma cell lines used here, 
suggesting that it is likely to be BRAF status-
independent.  
Membrane phospholipid metabolism is regulated by 
several processes including the cell cycle, with net 
phospholipid accumulation observed during S phase 
[24]. In our experiments, Hsp90 inhibition caused a 
G1/S cell cycle arrest in SKMEL28 cells, while the 
effects in CHL-1 cells were not statistically significant; 
GPC, however, increased in both cases. Therefore it is 
unlikely that the rise in GPC observed post Hsp90 
inhibitor treatment is related to an arrest in a particular 
phase of the cell cycle. 
Previous work has shown increased GPC in cells 
exposed to apoptosis inducing agents [37]. Although 
Hsp90 inhibitors are mainly cytostatic, they can in 
some cases induce apoptosis, albeit to a limited extent 
due to the anti-apoptotic effects of induced heat shock 
proteins, such as Hsp72 and Hsc70 [12, 16, 38]. Our 
measurements were performed on adherent cells which 
were largely non-apoptotic as shown by flow 
cytometry (Figure 1C). Therefore it is unlikely that the 
changes reported here could be linked to overt 
apoptosis, although we cannot rule out the involvement 
of early processes leading up to apoptosis. 
The decline in the PC/GPC ratio observed in every 
case is consistent with reduced malignant potential [26, 
35] following treatment with Hsp90 inhibitors and 
indicates a degree of normalization in cellular 
phospholipid metabolism post-therapy. 
As indicated above, GPC is produced following the 
hydrolysis of PtdCho via PLA2 and subsequently 
lysophospholipase, which results in simultaneous 
release of free fatty acids [25]. To explore the 
mechanistic basis for the rise in GPC detected here, we 
assessed the levels of free fatty acid chains post Hsp90 
inhibition. 
1H MRS analysis showed an increase in the 
–CH2+CH3 fatty acyl groups in 17-AAG-treated 
SKMEL28 cells concomitant with the accumulation in 
GPC. To better characterize the origin of these lipids, 
Nile red staining was performed. This showed that 17-
AAG treatment resulted in an increase in the signals 
originating from cytoplasmic mobile lipid droplets, 
which are believed to contain the –CH2+CH3 fatty acyl 
chains detectable by MRS [39, 40]. Taken together 
these data support the involvement of a phospholipase 
A2 activity in the metabolic alterations observed 
following Hsp90 inhibition.  
The PLA2 superfamily consists of many members, 
of which three main types are distinguishable: the 
cytosolic calcium-dependent (cPLA2), cytosolic 
calcium-independent (iPLA2), and the secreted 
(sPLA2) PLA2 [34]. To determine the particular 
isoform involved in the observed metabolic changes, 
we initially investigated the expression and status of 
activation (by phosphorylation) of the widely reported 
and well characterized cPLA2 using Western blotting. 
This analysis indicated that the levels of cPLA2 and 
phospho-cPLA2 (the active form) were markedly 
reduced upon exposure to 17-AAG (an effect that to 
our knowledge has not been previously reported). 
Therefore it is unlikely that this enzyme could be 
involved in the increased generation of GPC observed 
here. This result was not surprising since a previous 
study showed that cPLA2 is activated by mitogenic 
signaling (which, at least for ERK1/2, is inhibited by 
17-AAG in this study) leading to arachidonic acid 
mobilization, necessary for the inflammatory response 
[41], in line with the reported anti-inflammatory effects 
of Hsp90 inhibition [42]. 
On the other hand, iPLA2 has been implicated in 
phospholipid remodeling and in GPC release to 
maintain cellular lipid homeostasis [43]. Due to the 
lack of good commercially available antibodies for 
iPLA2 (and sPLA2), we could not evaluate the 
expression of these enzymes following exposure to 17-
AAG. Therefore, to assess if iPLA2 could be 
implicated in the rise in GPC, 17-AAG-treated 
SKMEL28 cells were co-incubated with BEL,  a 
specific inhibitor of iPLA2 that has no activity against 
the other cellular PLA2s including cPLA2 and sPLA2 
[34]. Our results show that BEL treatment preserved 
the molecular response of Hsp90 inhibition without 
further significant reduction of cell counts. More 
importantly co-exposure to BEL prevented the 
accumulation in GPC recorded with 17-AAG alone 
with no significant effect on PC, GPE or NTP. This 
finding indicates that the rise in GPC seen with Hsp90 
inhibitors is likely to involve iPLA2 activation. 
Despite the fact that BEL is specific for iPLA2 over 
the other PLA2 sub-types, it also inhibits the 
magnesium-dependent phosphatidic acid phosphatase,  
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the enzyme that converts phosphatic acid into 
diacylglycerol, with similar potency [44]. However, as 
this activity is not involved in the synthesis of GPC, it 
is unlikely that the effects of BEL on GPC observed 
here could be linked to inhibition of enzymes other 
than iPLA2. We therefore conclude that activation of 
iPLA2, but not cPLA2, may be implicated in the 
accumulation of GPC content seen following Hsp90 
inhibition. The observation that PtdCho levels were not 
altered in 17-AAG-treated cells despite the presumed 
up-regulation of iPLA2 activity is consistent with the 
tight control of membrane PtdCho homeostasis and 
implies the involvement of other rate limiting enzymes 
in regulating this process.  
The exact molecular mechanism via which Hsp90 
inhibition impacts on iPLA2 activity needs further 
investigation. One possibility may be through 
phosphorylation of p38 MAPK occurring following 
Hsp90 inhibition [45] which has been shown to 
activate iPLA2 [46]. Future work will establish 
whether such events could be responsible for the 
changes observed in our study. 
We have shown that the rise in GPC was the most 
consistent change seen in SKMEL28 and CHL-1 
melanoma cell lines, and was seen with both Hsp90 
inhibitor chemotypes in SKMEL28 cells. This is in 
agreement with results from our previous work with 
17-AAG showing increased GPC levels in human 
colon cancer cells [28]. However, and in contrast to our 
earlier findings from that study, we did not observe a 
significant effect on PC levels following Hsp90 
inhibition in the human melanoma cell lines used here. 
Moreover, an in vivo study on prostate cancer 
xenografts has shown a reduction in total choline levels 
(comprising choline, PC and GPC) following 
administration of 17-AAG [29]; however, in that in 
vivo study there was significant apparent tumor 
heterogeneity following treatment with appearance of a 
potentially necrotic core, which may have altered the 
overall metabolite signature in vivo, and contributed to 
partial volume effects. The metabolic response in the 
absence of the tissue effects of treatment was not 
reported. We have previously noted metabolic changes 
in vivo that are proportional to the degree of volume 
response and to vascular changes [47]. The apparent 
discrepancy between the various results may indicate 
cell line and context-dependence and further 
investigation is required to define the basis for these 
differences in metabolic effects. 
In summary, our data show that Hsp90 inhibition 
results in increased GPC and reduced PC/GPC in 
human melanoma cells. This is coupled with elevated 
fatty acid signals and cytoplasmic mobile lipid droplet 
content.  The rise in GPC is reversed upon co-exposure 
to the iPLA2 specific inhibitor BEL, indicating the 
involvement of iPLA2 as a likely mechanism for the 
increase in the levels of this metabolite. This metabolic 
effect was concomitant with inhibition of oncogenic 
signal transduction and cell proliferation, and induction 
of differentiation in a manner that does not seem to be 
dependent on BRAF mutational status or on the 
particular cell cycle arrest profile induced in the 
melanoma cell lines studied here. 
These findings offer further insights into the 
biochemical processes modulated by Hsp90 inhibition 
in human melanoma cells, and provide a basis for 
future studies investigating metabolic changes as 
potential indicators of the anticancer activity exerted by 
Hsp90 inhibitors in malignant melanoma. 
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